Independent and cumulative association of clinical and morphological heart failure with long-term outcome after percutaneous coronary intervention.


Journal

Journal of cardiology
ISSN: 1876-4738
Titre abrégé: J Cardiol
Pays: Netherlands
ID NLM: 8804703

Informations de publication

Date de publication:
01 2021
Historique:
received: 15 02 2020
revised: 03 06 2020
accepted: 07 06 2020
pubmed: 6 9 2020
medline: 17 7 2021
entrez: 5 9 2020
Statut: ppublish

Résumé

Heart failure (HF) is a risk factor for adverse post-procedural outcome after revascularization; however, it is unclear how left ventricular systolic dysfunction (LVSD) and clinical HF symptoms affect percutaneous coronary intervention (PCI) outcomes. We investigated the characteristics and long-term outcomes of patients with clinical HF or LVSD after PCI. This was a Japanese multicenter registry study of adult patients receiving PCI. Among 4689 consecutive patients who underwent PCI at 15 hospitals from January 2009 to December 2012, we analyzed 2634 (56.2%) with documented left ventricular ejection fraction (LVEF). They were divided into four groups based on clinical HF (symptoms or HF hospitalization) and LVEF [≥35% and <35% (HF due to LVSD)]. The primary outcome was major adverse cardiovascular events (MACE), comprising all-cause death, acute coronary syndrome, HF hospitalization, performance of coronary artery bypass grafting, and stroke within 2 years after the initial PCI. Our findings revealed 354 patients (13.4%) with HF (clinical HF, n = 173, 48.9%; LVSD, n = 132, 37.3%; both, n = 49; 13.8%). The incidence of MACE was higher in patients with clinical HF or LVSD, and was largely due to higher non-cardiac death and HF hospitalization. After adjustment, clinical HF (hazard ratio 2.16, 95% confidence interval; 1.49-3.14) and lower LVEF (per 10%, hazard ratio 0.89, 95% confidence interval; 0.81-0.99) were independently associated with higher MACE risk. Clinical HF and LVSD were independently associated with adverse long-term clinical outcomes, particularly with non-cardiac death and HF readmission, in patients treated with PCI.

Sections du résumé

BACKGROUND
Heart failure (HF) is a risk factor for adverse post-procedural outcome after revascularization; however, it is unclear how left ventricular systolic dysfunction (LVSD) and clinical HF symptoms affect percutaneous coronary intervention (PCI) outcomes. We investigated the characteristics and long-term outcomes of patients with clinical HF or LVSD after PCI.
METHODS
This was a Japanese multicenter registry study of adult patients receiving PCI. Among 4689 consecutive patients who underwent PCI at 15 hospitals from January 2009 to December 2012, we analyzed 2634 (56.2%) with documented left ventricular ejection fraction (LVEF). They were divided into four groups based on clinical HF (symptoms or HF hospitalization) and LVEF [≥35% and <35% (HF due to LVSD)]. The primary outcome was major adverse cardiovascular events (MACE), comprising all-cause death, acute coronary syndrome, HF hospitalization, performance of coronary artery bypass grafting, and stroke within 2 years after the initial PCI.
RESULTS
Our findings revealed 354 patients (13.4%) with HF (clinical HF, n = 173, 48.9%; LVSD, n = 132, 37.3%; both, n = 49; 13.8%). The incidence of MACE was higher in patients with clinical HF or LVSD, and was largely due to higher non-cardiac death and HF hospitalization. After adjustment, clinical HF (hazard ratio 2.16, 95% confidence interval; 1.49-3.14) and lower LVEF (per 10%, hazard ratio 0.89, 95% confidence interval; 0.81-0.99) were independently associated with higher MACE risk.
CONCLUSIONS
Clinical HF and LVSD were independently associated with adverse long-term clinical outcomes, particularly with non-cardiac death and HF readmission, in patients treated with PCI.

Identifiants

pubmed: 32888830
pii: S0914-5087(20)30208-2
doi: 10.1016/j.jjcc.2020.06.014
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

41-47

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Auteurs

Mai Kimura (M)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Takashi Kohno (T)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan; Department of Cardiovascular Medicine, Kyorin University School of Medicine, Tokyo, Japan. Electronic address: kohno.a2@keio.jp.

Mitsuaki Sawano (M)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Paul A Heidenreich (PA)

Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.

Ikuko Ueda (I)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Toshiyuki Takahashi (T)

Department of Cardiology, Saiseikai Central Hospital, Tokyo, Japan.

Takashi Matsubara (T)

Department of Cardiology, Hiratsuka City Hospital, Kanagawa, Japan.

Koji Ueno (K)

Department of Cardiology, Saiseikai Utsunomiya Hospital, Tochigi, Japan.

Kentaro Hayashida (K)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Shinsuke Yuasa (S)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Takahiro Ohki (T)

Department of Cardiology, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan.

Keiichi Fukuda (K)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Shun Kohsaka (S)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH